- Home
- AMRN vs GNFT Comparison
AMRN vs GNFT Comparison
Compare AMRN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- GNFT
- Stock Information
- Founded
- AMRN 1989
- GNFT 1999
- Country
- AMRN Ireland
- GNFT France
- Employees
- AMRN N/A
- GNFT N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMRN Health Care
- GNFT Health Care
- Exchange
- AMRN Nasdaq
- GNFT Nasdaq
- Market Cap
- AMRN 189.2M
- GNFT 172.2M
- IPO Year
- AMRN 1993
- GNFT 2019
- Fundamental
- Price
- AMRN $0.55
- GNFT $3.45
- Analyst Decision
- AMRN Buy
- GNFT Strong Buy
- Analyst Count
- AMRN 1
- GNFT 1
- Target Price
- AMRN N/A
- GNFT $13.00
- AVG Volume (30 Days)
- AMRN 1.8M
- GNFT 6.9K
- Earning Date
- AMRN 02-27-2025
- GNFT 09-19-2024
- Dividend Yield
- AMRN N/A
- GNFT N/A
- EPS Growth
- AMRN N/A
- GNFT N/A
- EPS
- AMRN N/A
- GNFT 0.47
- Revenue
- AMRN $241,021,000.00
- GNFT $86,225,222.00
- Revenue This Year
- AMRN N/A
- GNFT $145.20
- Revenue Next Year
- AMRN N/A
- GNFT N/A
- P/E Ratio
- AMRN N/A
- GNFT $7.17
- Revenue Growth
- AMRN N/A
- GNFT 175.45
- 52 Week Low
- AMRN $0.43
- GNFT $3.33
- 52 Week High
- AMRN $1.37
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- AMRN 60.15
- GNFT 29.90
- Support Level
- AMRN $0.43
- GNFT $3.35
- Resistance Level
- AMRN $0.49
- GNFT $3.57
- Average True Range (ATR)
- AMRN 0.04
- GNFT 0.12
- MACD
- AMRN 0.01
- GNFT 0.00
- Stochastic Oscillator
- AMRN 88.57
- GNFT 17.27
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.